Q1 2026 earnings recap / CEO transition / FY26 guide / legal catalysts
Key Questions
What were UnitedHealth's FY25 financial results?
FY25 revenue reached $447.6B with EPS of $13.23, beating estimates. Q4 2025 showed $113.2B revenue (+12.3% YoY) and EPS $2.11, with MLR at 88.8-88.9%. Pre-earnings Zacks ESP was $6.62-6.69.
What is UNH's FY26 guidance?
FY26 revenue is guided at $439B, down 2% YoY, with 47M MA members and 2.3-2.8M exits. Targets include $1-1.6B AI savings, over $24B ops efficiencies, testing moat amid CEO fixes. Q1 revenue expected flat at $109.6B, EPS down 8% YoY.
What legal settlements did UNH announce?
UNH settled $1.4M for NY mental health issues. Ongoing probes and litigation headwinds persist alongside cost pressures. Peers showed mixed results.
How have analysts rated UNH ahead of Q1 earnings?
75% positive pre-April 21 sentiment, Zacks Strong Buy consensus. Raymond James upgraded to Outperform with $330 PT, BofA $337, citing AI and earnings power. TipRanks notes bullish trend among top analysts.
What factors could drive UNH margin recovery?
G&A and Optum savings, clinic closures, CMS '27 rates, and Stars relief are key. New CEO Hemsley focuses on ops fixes amid med cost caution. AI initiatives target $1-1.6B opex saves.
Is UNH a buy before earnings historically?
UNH has risen 75% of the time in the 2 weeks before earnings, averaging 2.4% gain. Analysts like Raymond James see Wall Street underestimating earnings. Motley Fool questions if down 50% from high makes it a steal.
What are the main challenges for UNH in 2026?
Turnaround hinges on execution vs. probes, med costs, MA caution, and membership exits. Legal headwinds and cost pressures overshadow fundamentals. Peers mixed, but AI/Optum moat tested.
Will UNH beat Q1 estimates?
Zacks expects a beat based on history; ESP positive. Revenue flat, EPS down YoY but upgrades cite upside potential. Preview highlights earnings power underestimation.
FY25 $447.6B/$13.23 EPS beat/Q4'25 $113.2B +12.3%/EPS$2.11/MLR88.8-88.9%; FY26 $439B -2%YoY/47M MA/2.3-2.8M exits/Hemsley fixes ops/$1-1.6B AI saves/>$24B ops tgt moat test; $1.4M NY/mental health settlements; pre-Apr21 75% pos/Zacks ESP $6.62-6.69/-8% YoY/rev$109.6B flat/Strong Buy cons; med costs/MA caut but G&A/Optum savings/clinic shuts margin recovery; peers mixed; RJ/BofA $330-337 AI; CMS '27/Stars relief tailwind; turnaround hinges on 2026 execution vs probes.